Deutsche Bank hires Glen Santangelo to lead Healthcare Technology & Distribution research

Deutsche Bank today announced the hiring of Glen Santangelo to lead US Equity Research coverage of the Healthcare Technology & Distribution sector. Today’s announcement rounds out a year-long investment in Healthcare at Deutsche Bank.

“Over the past year, we have invested strategically and significantly in our Healthcare research platform,” said Steve Pollard, Deutsche Bank Global Head of Equity Research. “Our platform now offers clients comprehensive Healthcare research coverage designed to match their sector needs with an ability to generate unique market insight.”

“Healthcare is a clear area of investment across CIB in the Americas,” added Mark Fedorcik, co-head of Americas CIB. “We are committed to making hires that reinforce our client offering and position us well in this active sector.”

Glen Santangelo will join the bank in July as a Managing Director. Santangelo has more than 20 years of experience in healthcare research and joins from Credit Suisse where he was US Co-Director of Research. Prior to that, he led the Credit Suisse Healthcare team and was named to the Institutional Investor All-American Research Team for seven consecutive years beginning in 2009. He received his BS in Accounting from Villanova University and his MBA from New York University. Santangelo will be based in New York and report to Steve Pollard.

Over the past twelve months, the bank has also hired Chris Rigg to cover Healthcare Services, Dan Leonard to cover Life Science & Diagnostics Tools, and Andrew Peters and Navin Jacob to cover Biotechnology. The analysts all report to Steve Pollard.

Navin Jacob and Andrew Peters joined Deutsche Bank in March 2017 and May 2016, respectively, as Directors to cover the US Biotechnology sector. Prior to joining Deutsche Bank, Jacob was a senior analyst covering Global Pharmaceuticals at Healthcor Management and earlier covered US Biotech & Pharmaceuticals at Citadel Asset Management. Jacob received his BA in Biochemistry at Cornell University. He is based in New York. Prior to joining, Peters was a Director and led the Small & Mid Cap Biotechnology franchise at UBS. Peters received his Master of Bioscience and MBA from Claremont McKenna College. He is based in San Francisco.

Chris Rigg joined Deutsche Bank in January 2017 as a Director and equity research analyst covering the Healthcare Facilities & Managed Care sector. Prior to joining Deutsche Bank, Rigg was a senior Managed Care & Healthcare Facilities analyst at Susquehanna Financial Group and was named one of Institutional Investor’s ‘Rising Stars of Wall Street.’ Rigg received his BA in Business Administration and History from Muhlenberg College and his MBA from New York University. He is based in New York.

Dan Leonard joined Deutsche Bank in September 2016 as a Director and equity research analyst covering the Life Science & Diagnostic Tools sector. Prior to joining Deutsche Bank, Leonard was a senior Life Science and Diagnostic Tools analyst at Leerink Partners. Leonard received his MBA with Honors from The Booth School of Business at the University of Chicago and his BA in Economics with Distinction from the University of Michigan. He is based in New York.

The investment in US Equity Research has been complemented with new hires in Investment Banking. Deutsche Bank recently announced the hiring of Phillip Pucciarelli as a Managing Director and Co-Head of Americas Healthcare Investment Banking, alongside Ross Hammerman who joined the bank in July 2016. It also hired Robert Verdier as a Managing Director in Healthcare Services, Nick Richitt as a Managing Director focused on Healthcare IT and Outsourcing, William White as a Managing Director and Head of US Life Sciences, Glenn Rewick as a Managing Director in M&A focused on Healthcare, and Matt Jackson as a Director focused on Healthcare.

About Deutsche Bank

Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations and the assumptions underlying them. These statements are based on plans, estimates and projections as they are currently available to the management of Deutsche Bank. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.

By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include the conditions in the financial markets in Germany, in Europe, in the United States and elsewhere from which we derive a substantial portion of our revenues and in which we hold a substantial portion of our assets, the development of asset prices and market volatility, potential defaults of borrowers or trading counterparties, the implementation of our strategic initiatives, the reliability of our risk management policies, procedures and methods, and other risks referenced in our filings with the U.S. Securities and Exchange Commission. Such factors are described in detail in our SEC Form 20-F of 11 March 2016 under the heading “Risk Factors”. Copies of this document are readily available upon request or can be downloaded from www.db.com/ir.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170725006306/en/